Journal of Nuclear Cardiology

, Volume 26, Issue 3, pp 701–703 | Cite as

Cardiovascular disease in the literature: A selection of recent original research papers

  • Wael A. AlJaroudi
  • Fadi G. HageEmail author
Review of the Literature

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.N Engl J Med.2019;380:752-62

Background: Inflammation is a causal factor in the development and progression of coronary artery disease (CAD). Low-dose methotrexate (LDM) is an inexpensive and effective anti-inflammatory agent that is widely used for the treatment of rheumatoid arthritis and other inflammatory diseases. Ridker et al from the Brigham and Women’s Hospital, Boston randomized in a double-blind fashion after a run-in period, 4786 patients with diabetes mellitus or metabolic syndrome who have prior myocardial infarction or multivessel to LDM or placebo. All participants received 1 mg of folate daily. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina.

Findings:At the end of the trial (median follow-up of 2.3 years) 21% of the LDM group and 22% of placebo group had permanently discontinued study drug. The...



Dr. Hage reports research grant support from Astellas pharma and GE Healthcare.

Copyright information

© American Society of Nuclear Cardiology 2019

Authors and Affiliations

  1. 1.Division of Cardiovascular MedicineClemenceau Medical CenterBeirutLebanon
  2. 2.Division of Cardiovascular Disease, Department of MedicineUniversity of Alabama at BirminghamBirminghamUSA
  3. 3.Section of CardiologyBirmingham Veterans Affairs Medical CenterBirminghamUSA

Personalised recommendations